Medscape |
Glucagon Receptor Antagonist Shows Early Promise in Type 1 Diabetes
Medscape SAN DIEGO — An investigational glucagon receptor antagonist — the human antibody REMD-477 (REMD Biotherapeutics) — has shown promise in a 26-day, phase 1 study of patients with type 1 diabetes. Specifically, those who received a single ... Thank you, Diane Abbott, for speaking out about your diabetes | Ann ... Finger Pricks to Test Diabetes Blood Sugar Often Not Needed Type 2 diabetes study shows benefits of vegetarian diet |
Social Plugin